UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/674,962	11/08/2000	Bernhard Hauer	49041	7018

7590   03/27/2002

Keil & Weinkauf
1101 Connecticut Avenue NW
Washington, DC   20036

EXAMINER
BHATTI, TAHIRA H

ART UNIT	PAPER NUMBER
1627	

DATE MAILED: 03/27/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/674,962			

EXAMINER	
Tahira Bhatti	
ART UNIT	PAPER NUMBER
1627	5

DATE MAILED:

RECEIVED APR 29 2002

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication should be directed toTahira Bhatti whose telephone number is (703) 605-1203. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

Tahira Bhatti
Patent Examiner
Technology center 1600
Art Unit 1627
Nov 27, 2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirement for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.8

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence List as required by 37 CFR 1.821(e).

☐ 7. Other: ———

Applicant must provide:

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, inclu new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123
For CRF submission help, call (703) 308-4212
For PatentIn software help, call (703) 308-6856

Please return a copy of this notice with your response.

SEQUENCE LISTING

<110> Hauer, Bernhard
       Schmid, Rolf D.
       Enzelberger, Markus
       Minning, Stephan

<120> Novel Peptide Fragments for Purifying Proteins

<130> 49041/Up

<140> 09/674,962

<141> 2000-11-08

<150> PCT/EP99/03469

<151> 1999-05-20

<160> 10

<170> WordPerfect version 6.1

<210> 1
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<222> 1..10
<223> sequence for purifying proteins

<221> unsure
<222> 2
<223> Xaa is an amino acid selected from the group consisting of
Ala, Val, Phe, Ser, Met, Trp, Tyr, Asn, Asp and Lys, particularly preferably
Phe, Ser, Asn, Asp and Lys, very particularly preferably Asn.

<221>   unsure
<222> 4
<223>   Xaa is an amino acid selected from the group consisting of
Val, Ile, Phe, Pro, Trp, Tyr, Gln, Glu and Arg, particularly preferably Val,
Ile, Phe, Pro, Gln, Glu and Arg,
<223> very particularly preferably Gln, Glu and Arg.

<221> unsure
<222> 5
<223> Xaa is an amino acid selected from the group consisting of
Gly, Ile, Thr, Met, Trp, Tyr, Asn, Gln, Asp, Glu, Lys, Arg and His,
particularly preferably Gly, Ile, Thr, Met, Trp, Tyr, Asn Asp, Glu, Arg and
His,

<223> very particularly preferably Gly, Thr and Tyr.

<221> unsure
<222> 6
<223> Xaa is an amino acid selected from the group consisting of

Val, Phe, Pro, Cys, Met, Trp, Asn, Glu, Arg and His, particularly preferably
Val, Phe, Cys, Met, Trp, Asn, Arg and His, very particularly preferably Asn
and Arg.

<221> unsure
<222> 8
<223> Xaa is an amino acid selected from the group consisting of
Gly, Ser, Cys, Met, Trp, Asn, Glu, Lys and Arg, particularly preferably Gly,
Ser, Cys, Met, Asn, Glu, Lys and Arg, very particularly preferably Gly and
Lys.

<221> unsure
<222> 9
<223> Xaa is an amino acid selected from the group consisting of
Gly, Ser, Cys, Met, Trp, Asn, Glu, Lys and Arg, particularly preferably Gly,
Ser, Cys, Met, Asn, Glu, Lys and Arg, very particularly preferably Gly and
Lys.

<400> 1

His Xaa His Xaa Xaa Xaa Cys Xaa Xaa Cys
1   5   10

<210> 2
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Sequence for purifying proteins

<400> 2

His Gln His Glu Gly Arg Cys Lys Glu Cys
1   5   10

<210> 3
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Sequence for purifying proteins

<400> 3

His Asn His Arg Tyr Gly Cys Gly Cys Cys
1   5   10

<210> 4
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Sequence for purifying proteins

<400> 4

His Arg His Gly Thr Asn Cys Leu Lys Cys
1   5   10

<210> 5
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Sequence for purifying proteins

<400> 5

His Ile His Gln Ser Asn Cys Gln Val Cys
1   5   10

<210> 6
<211>   59
<212>   DNA
<213>   Artificial sequence

<220>
<221> unsure
<222> 1..59
<223> primer
<223> n is a, g, c, t or u

<400> 6

gcaataccat ggggcatnnn catnnnnnnn nntgtnnnnn ntgtgtgagg aagggcgag   59

<210> 7
<211>   17
<212>   DNA
<213>   Artificial sequence

<220>
<223> primer

<400> 7

cagttggaat tctagag   17

<210> 8
<211>   47
<212>   DNA
<213>   Artificial sequence

<220>
<223> primer

<400> 8

gcaataccat ggggcatcat catcatcatc atgtgaggaa gggcgag   47

<210> 9

<211>   17
<212>   DNA
<213>   Artificial sequence

<220>
<223> primer

<400> 9

cagttggaat tctagag   17

<210> 10
<211>   44
<212>   DNA
<213>   Artificial sequence

<220>
<223> primer

<400> 10

gcaataccat ggggcatatt cataatcttg attgtcctga ttgt   44